Navigation Links
iPierian Appoints Dr. Chad Cowan and Dr. Konrad Hochedlinger to Scientific Advisory Board
Date:8/6/2009

SOUTH SAN FRANCISCO, Calif., Aug. 6 /PRNewswire/ -- iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced the appointments of Dr. Chad Cowan and Dr. Konrad Hochedlinger to the company's Scientific Advisory Board (SAB).

"Drs. Cowan and Hochedlinger are leading scientists in stem cell research and their addition to the iPierian SAB rounds out an exemplary group of scientists. The collective expertise of this SAB will further our efforts of developing disease-relevant models to discover drugs, and translating these efforts into new therapies for patients," said John P. Walker, chief executive officer of iPierian.

Dr. Chad Cowan is assistant professor of Medicine at Harvard Medical School and the Department of Stem Cell and Regenerative Biology, and assistant investigator at Stowers Medical Institute. His research focuses on adipogenesis, metabolic disease, and the impact of environmental and genetic factors on the development of disease.

Dr. Konrad Hochedlinger is assistant professor of Medicine at Harvard Medical School and the Department of Stem Cell and Regenerative Biology, principal faculty member at the Harvard Stem Cell Institute and investigator at the Massachusetts General Hospital Cancer Center and Center for Regenerative Medicine. Dr. Hochedlinger is a leader in reprogramming technology and produced the first transgene-free induced pluripotent stem (iPS) cells. Most recently, Dr. Hochedlinger received the International Society for Stem Cell Research (ISSCR) Outstanding Young Investigator Award.

About iPierian

iPierian is a South San Francisco-based biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells. iPierian is backed by Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease as well as in cardiovascular disease, where iPierian has a collaboration with The Gladstone Institute of Cardiovascular Disease and Dr. Deepak Srivastava, the institute's director. iPierian plans to enhance its partnership efforts to further expand into metabolic diseases. Earlier this year, the company announced a formal collaboration with the laboratory of Dr. Shinya Yamanaka of Kyoto University to develop and improve methods of deriving iPS cell lines in order to advance iPS cell technology.

Because iPS cells are believed to be able to grow indefinitely in culture and to differentiate into many cell types, iPS cells have great potential for disease research, preclinical drug testing and cell-based therapy. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success for drug candidates. iPierian plans to use precise human disease models to find new molecular targets and develop proprietary therapeutic small molecule or biologic drugs for its own pipeline to treat specific diseases.


'/>"/>
SOURCE iPierian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Streamline Health Appoints Jon Phillips Chairman of the Board of Directors
2. Novo Nordisk Appoints Per Falk, M.D., Ph.D., as Vice President for Clinical, Medical and Regulatory Affairs for North America
3. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
4. Globaltel Media Appoints Leading Healthcare Industry Veterans to Advisory Board
5. Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors
6. Red Cross Appoints Peggy Dyer as Chief Marketing Officer
7. MonoSol Rx Appoints Theodore Clemente Vice President Business Development
8. WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology
9. Webmedx Appoints New Senior Vice President of Client Development, Chris Cashwell
10. Immucor Appoints Chief Operating Officer
11. DaVita Clinical Research Appoints Mahesh Krishnan as Vice President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/4/2017)... Oct. 4, 2017  According to the Centers for Disease Control and ... October . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the ... certain health insurance regulations. ... time to get a flu shot is by the end of October, ...
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology: